GIM
VRTX icon

Goelzer Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Goelzer Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Sell
871
-76
-8% -$33.7K 0.02% 245
2026
Q1 		$423K Sell
947
-923
-49% -$430K 0.02% 236
2025
Q4 		$848K Buy
1,870
+4
+0.2% +$1.72K 0.04% 171
2025
Q3 		$731K Sell
1,866
-33
-2% -$13.8K 0.04% 165
2025
Q2 		$845K Buy
1,899
+6
+0.3% +$2.77K 0.05% 157
2025
Q1 		$918K Sell
1,893
-22
-1% -$10.3K 0.05% 147
2024
Q4 		$771K Buy
1,915
+29
+2% +$13.4K 0.04% 152
2024
Q3 		$877K Buy
1,886
+14
+0.7% +$6.72K 0.05% 145
2024
Q2 		$877K Sell
1,872
-12
-0.6% -$5.21K 0.05% 146
2024
Q1 		$788K Sell
1,884
-17
-0.9% -$7.19K 0.04% 154
2023
Q4 		$773K Sell
1,901
-214
-10% -$79.1K 0.05% 151
2023
Q3 		$735K Buy
2,115
+169
+9% +$59.1K 0.05% 147
2023
Q2 		$685K Sell
1,946
-132
-6% -$44.5K 0.06% 151
2023
Q1 		$655K Sell
2,078
-103
-5% -$30.9K 0.06% 158
2022
Q4 		$630K Buy
2,181
+40
+2% +$12.2K 0.05% 167
2022
Q3 		$620K Buy
2,141
+147
+7% +$42.3K 0.06% 163
2022
Q2 		$562K Buy
1,994
+188
+10% +$50.3K 0.05% 168
2022
Q1 		$471K Buy
1,806
+98
+6% +$23.3K 0.04% 179
2021
Q4 		$375K Sell
1,708
-9,609
-85% -$1.87M 0.03% 200
2021
Q3 		$2.05M Buy
11,317
+6
+0.1% +$1.17K 0.18% 139
2021
Q2 		$2.28M Buy
11,311
+58
+0.5% +$12.1K 0.19% 139
2021
Q1 		$2.42M Buy
11,253
+1,887
+20% +$414K 0.21% 132
2020
Q4 		$2.21M Buy
9,366
+982
+12% +$225K 0.2% 131
2020
Q3 		$2.28M Buy
8,384
+22
+0.3% +$6.07K 0.21% 122
2020
Q2 		$2.43M Buy
8,362
+321
+4% +$87K 0.23% 117
2020
Q1 		$1.91M Buy
8,041
+3,037
+61% +$697K 0.22% 119
2019
Q4 		$1.1M Buy
+5,004
New +$1.01M 0.09% 166

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

Goelzer Investment Management's VRTX Position: Q2 2026 in Review

Goelzer Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 8% in Q2 2026, selling an estimated $33.7K and leaving 871 shares worth $433K. The position accounts for 0.02% of the portfolio, ranked #245.

Goelzer Investment Management first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.43M in Q2 2020. 368 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Goelzer Investment Management held 871 shares of Vertex Pharmaceuticals worth $433K as of Q2 2026.
  • Goelzer Investment Management sold 76 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
  • Vertex Pharmaceuticals made up 0.02% of Goelzer Investment Management's portfolio in Q2 2026, its #245 holding.
  • Goelzer Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Goelzer Investment Management's Vertex Pharmaceuticals position peaked at $2.43M in Q2 2020.
  • 368 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Goelzer Investment Management's 13F filing for Q2 2026, filed 15 Jul 2026.